Profile - To The Moon

AyuNg

Posts · 5Posts · 5
Following · 0Following · 0
Followers · 0Followers · 0

- AyuNgAyuNg
  ·2021-03-17
  Roger
  3 Cancer Diagnostic Stocks To Watch Following Roche's GenMark Buy
  Roche Holding AGRHHBY 0.17%acquiredGenMark Diagnostics, Inc(NASDAQ: GNMK) in a$1.8 billion deal on M
  3 Cancer Diagnostic Stocks To Watch Following Roche's GenMark Buy
  53 Comment
  Like
  Share
  Report
- AyuNgAyuNg
  ·2021-03-10
  ?
  Sorry, this post has been deleted
  17 Comment
  Like
  Share
  Report
- AyuNgAyuNg
  ·2021-03-09
  Good
  Buy Target Stock on the Dip, Analyst Says
  Targetstock soared in 2020, as the Covid-19 pandemic funneled millions of new customers to its store
  Buy Target Stock on the Dip, Analyst Says
  106 Comment
  Like
  Share
  Report
- AyuNgAyuNg
  ·2021-03-08
  Gosh
  Elon Musk lost $27 billion last week
  New York (CNN Business)Elon Musk's net worth plunged last week as tech stocks got hammered and Tesla
  Elon Musk lost $27 billion last week
  5 Comment
  Like
  Share
  Report
- AyuNgAyuNg
  ·2021-03-08
  to him is just a small money
  Sorry, this post has been deleted
  82 Comment
  Like
  Share
  Report

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3572376808674205","uuid":"3572376808674205","gmtCreate":1609290870066,"gmtModify":1609294017847,"name":"AyuNg","pinyin":"ayung","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/33c17b1cfc356a899e4c538a20ed5530","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":29,"tweetSize":5,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.12.26","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.23%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"60.30%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":325442335,"gmtCreate":1615924922527,"gmtModify":1704788518530,"author":{"id":"3572376808674205","authorId":"3572376808674205","name":"AyuNg","avatar":"https://static.tigerbbs.com/33c17b1cfc356a899e4c538a20ed5530","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572376808674205","authorIdStr":"3572376808674205"},"themes":[],"htmlText":"Roger","listText":"Roger","text":"Roger","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/325442335","repostId":"1178891078","repostType":4,"repost":{"id":"1178891078","kind":"news","pubTimestamp":1615909549,"share":"https://ttm.financial/m/news/1178891078?lang=&edition=fundamental","pubTime":"2021-03-16 23:45","market":"us","language":"en","title":"3 Cancer Diagnostic Stocks To Watch Following Roche's GenMark Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=1178891078","media":"Benzinga","summary":"Roche Holding AGRHHBY 0.17%acquiredGenMark Diagnostics, Inc(NASDAQ: GNMK) in a$1.8 billion deal on M","content":"<p><b>Roche Holding AG</b>RHHBY 0.17%acquired<b>GenMark Diagnostics, Inc</b>(NASDAQ:&nbsp;GNMK) in a$1.8 billion deal&nbsp;on Monday, the same day&nbsp;<b>Veracyte Inc</b>&nbsp;VCYT 1.76%announcedit completed the&nbsp;acquisition of<b>Decipher Biosciences, Inc.</b></p>\n<p><b>What Happened:</b>With thecancer diagnostic marketexpected to grow to $261.34 billion by 2027 — more than double the $115.60 billion it was worth last year — big biotech companies have been on an acquisition spree to boost their portfolios and&nbsp;technology.</p>\n<p>In January,&nbsp;<b>Exact Sciences Corporation</b>&nbsp;EXAS 3.64%announcedit completed its acquisition of<b>Thrive Earlier Detection Corp.</b>and&nbsp;got Thrive’s&nbsp;blood-based multi-cancer detection technology.</p>\n<p><b>Why It Matters:</b>Early detection of cancer greatly increases the survival rate and smaller biotech companies are showing leadership skills in developing the necessary technology.</p>\n<p>Smaller companies develop specific technology for specific types of cancer which allows them to focus on creating tailored products that are also&nbsp;attractive for larger companies&nbsp;to acquire.</p>\n<p>The following three companies have developed technology that could make them sought-after acquisition targets:</p>\n<p><b>BioMark&nbsp;Diagnostics Inc</b>BMKDF 13.17%, a biotech company headquartered in Vancouver, British Columbia, has developed a state-of-the-art liquid biopsy technology platform for the early detection of cancer. The unique technologyfinds metabolomicsbiomarkers of hard-to-detect cancers of the lung, brain, ovarian and pancreas.</p>\n<p>BioMark&nbsp;is pivoting into commercialization after many years in the research and development phase. On Feb. 16, the company&nbsp;announced&nbsp;it will collaborate with&nbsp;Phytronix&nbsp;Technologies Inc “to advance the development of&nbsp;BioMark’s&nbsp;early lung cancer screening applications using&nbsp;Phytronix-proprietary Laser Diode Thermal Desorption (LDTD) technology,”&nbsp;BioMark&nbsp;said in a press release.</p>\n<p>The collaboration will also support&nbsp;BioMark&nbsp;in setting up clinical lab services in Quebec.&nbsp;BioMark&nbsp;plans to demonstrate its technology later in 2021.</p>\n<p>BioMark’s&nbsp;market cap is $28.67 million and its shares are at 41 cents, up 13.17% on Tuesday morning.</p>\n<p><b>Biocept Inc</b>BIOC 0.17%is another company focusing on early cancer detection through blood-based liquid biopsy. The San Diego-based company has two platforms, CTC&nbsp;and&nbsp;ctDNA, used to detect and analyze a patient’s blood for cancer cells and mutations.</p>\n<p>Biocept boasts22 patentsfor its liquid-biopsy technology in the U.S., EU, Australia, China, Japan and South Korea.</p>\n<p>On Feb. 16, Bioceptannounced&nbsp;its product, Target Selector, is ultra-sensitive and capable of detecting mutations using biopsy specimens&nbsp;usually be deemed “quantity not sufficient.”</p>\n<p>In a pivot brought on by the pandemic, Biocept alsoannounced&nbsp;on Feb. 3&nbsp;its lab had processed 250 000 COVID-19 tests using its RT-PCR technology.</p>\n<p>Biocept has a market cap of $79.98 million and the company's&nbsp;shares are at $5.87, down 1.68% Tuesday morning.</p>\n<p><b>HTG Molecular Diagnostics Inc</b>HTGM 3.29%, an Arizona-based biotech company, developed the EdgeSeq&nbsp;Oncology Biomarker Panel to detect colon, breast, prostate and lung cancer from tumor tissue. The analysis tool can detect2,549 genesassociated with tumor biology and results are available only 36 hours following the biopsy collection.</p>\n<p>Unlike&nbsp;BioMark&nbsp;and Biocept, HTG Molecular uses Formalin-Fixed Paraffin-Embedded (FFPE) tissue specimens to test for cancers.</p>\n<p>On Feb. 26, HTG Molecularannouncedits&nbsp;EdgeSeq&nbsp;technology “demonstrated the ability to generate unique gene expression profiles for multiple cancer indications” and the amount of tissue required in the samples was 4 to 8 times less than required for similar tests.</p>\n<p>HTG Molecular has a market cap of $28.82 million and its shares area t $6.17, up 1.48% on Tuesday morning.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Cancer Diagnostic Stocks To Watch Following Roche's GenMark Buy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Cancer Diagnostic Stocks To Watch Following Roche's GenMark Buy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-16 23:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/general/biotech/21/03/20187640/3-cancer-diagnostic-stocks-to-watch-following-roches-genmark-buy><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Roche Holding AGRHHBY 0.17%acquiredGenMark Diagnostics, Inc(NASDAQ: GNMK) in a$1.8 billion deal on Monday, the same day Veracyte Inc VCYT 1.76%announcedit completed the acquisition ofDecipher ...</p>\n\n<a href=\"https://www.benzinga.com/general/biotech/21/03/20187640/3-cancer-diagnostic-stocks-to-watch-following-roches-genmark-buy\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/general/biotech/21/03/20187640/3-cancer-diagnostic-stocks-to-watch-following-roches-genmark-buy","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178891078","content_text":"Roche Holding AGRHHBY 0.17%acquiredGenMark Diagnostics, Inc(NASDAQ: GNMK) in a$1.8 billion deal on Monday, the same day Veracyte Inc VCYT 1.76%announcedit completed the acquisition ofDecipher Biosciences, Inc.\nWhat Happened:With thecancer diagnostic marketexpected to grow to $261.34 billion by 2027 — more than double the $115.60 billion it was worth last year — big biotech companies have been on an acquisition spree to boost their portfolios and technology.\nIn January, Exact Sciences Corporation EXAS 3.64%announcedit completed its acquisition ofThrive Earlier Detection Corp.and got Thrive’s blood-based multi-cancer detection technology.\nWhy It Matters:Early detection of cancer greatly increases the survival rate and smaller biotech companies are showing leadership skills in developing the necessary technology.\nSmaller companies develop specific technology for specific types of cancer which allows them to focus on creating tailored products that are also attractive for larger companies to acquire.\nThe following three companies have developed technology that could make them sought-after acquisition targets:\nBioMark Diagnostics IncBMKDF 13.17%, a biotech company headquartered in Vancouver, British Columbia, has developed a state-of-the-art liquid biopsy technology platform for the early detection of cancer. The unique technologyfinds metabolomicsbiomarkers of hard-to-detect cancers of the lung, brain, ovarian and pancreas.\nBioMark is pivoting into commercialization after many years in the research and development phase. On Feb. 16, the company announced it will collaborate with Phytronix Technologies Inc “to advance the development of BioMark’s early lung cancer screening applications using Phytronix-proprietary Laser Diode Thermal Desorption (LDTD) technology,” BioMark said in a press release.\nThe collaboration will also support BioMark in setting up clinical lab services in Quebec. BioMark plans to demonstrate its technology later in 2021.\nBioMark’s market cap is $28.67 million and its shares are at 41 cents, up 13.17% on Tuesday morning.\nBiocept IncBIOC 0.17%is another company focusing on early cancer detection through blood-based liquid biopsy. The San Diego-based company has two platforms, CTC and ctDNA, used to detect and analyze a patient’s blood for cancer cells and mutations.\nBiocept boasts22 patentsfor its liquid-biopsy technology in the U.S., EU, Australia, China, Japan and South Korea.\nOn Feb. 16, Bioceptannounced its product, Target Selector, is ultra-sensitive and capable of detecting mutations using biopsy specimens usually be deemed “quantity not sufficient.”\nIn a pivot brought on by the pandemic, Biocept alsoannounced on Feb. 3 its lab had processed 250 000 COVID-19 tests using its RT-PCR technology.\nBiocept has a market cap of $79.98 million and the company's shares are at $5.87, down 1.68% Tuesday morning.\nHTG Molecular Diagnostics IncHTGM 3.29%, an Arizona-based biotech company, developed the EdgeSeq Oncology Biomarker Panel to detect colon, breast, prostate and lung cancer from tumor tissue. The analysis tool can detect2,549 genesassociated with tumor biology and results are available only 36 hours following the biopsy collection.\nUnlike BioMark and Biocept, HTG Molecular uses Formalin-Fixed Paraffin-Embedded (FFPE) tissue specimens to test for cancers.\nOn Feb. 26, HTG Molecularannouncedits EdgeSeq technology “demonstrated the ability to generate unique gene expression profiles for multiple cancer indications” and the amount of tissue required in the samples was 4 to 8 times less than required for similar tests.\nHTG Molecular has a market cap of $28.82 million and its shares area t $6.17, up 1.48% on Tuesday morning.","news_type":1},"isVote":1,"tweetType":1,"viewCount":53,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":323614248,"gmtCreate":1615337702284,"gmtModify":1704781304797,"author":{"id":"3572376808674205","authorId":"3572376808674205","name":"AyuNg","avatar":"https://static.tigerbbs.com/33c17b1cfc356a899e4c538a20ed5530","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572376808674205","authorIdStr":"3572376808674205"},"themes":[],"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/323614248","repostId":"1146881306","repostType":4,"isVote":1,"tweetType":1,"viewCount":17,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":329695488,"gmtCreate":1615237079044,"gmtModify":1704779926934,"author":{"id":"3572376808674205","authorId":"3572376808674205","name":"AyuNg","avatar":"https://static.tigerbbs.com/33c17b1cfc356a899e4c538a20ed5530","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572376808674205","authorIdStr":"3572376808674205"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/329695488","repostId":"1130305981","repostType":4,"repost":{"id":"1130305981","kind":"news","pubTimestamp":1615217480,"share":"https://ttm.financial/m/news/1130305981?lang=&edition=fundamental","pubTime":"2021-03-08 23:31","market":"us","language":"en","title":"Buy Target Stock on the Dip, Analyst Says","url":"https://stock-news.laohu8.com/highlight/detail?id=1130305981","media":"Barrons","summary":"Targetstock soared in 2020, as the Covid-19 pandemic funneled millions of new customers to its store","content":"<p>Targetstock soared in 2020, as the Covid-19 pandemic funneled millions of new customers to its stores and website, yet that rally has stalled as investors look toward an end to the crisis. Yet Guggenheim argues that Target’s advantage is here to stay, and that selloff is a buying opportunity.</p>\n<p>Analyst Robert Drbul boosted his rating on Target (ticker: TGT) to Buy from Neutral, and established a $200 price target on Monday. He writes that he has “admired the execution and performance of the company over the past year and have been waiting for a pullback to become more constructive.” With the shares off some 6% last week,despite another upbeat earnings report, that time has come.</p>\n<p>Drbul sees three main reasons to be bullish on Target. First, he notes the tremendous growth the company saw last year, when it grew revenue by $15 billion, more than the company had grown over the prior 11 years combined.</p>\n<p>“Target proved fulfill-from-store can work, driving share gains and meeting an unprecedented demand led by a rise in digital demand,” he writes, and while he had “stubbornly been skeptical” of the company’s ability to execute as well as major competitors such asWalmart(WMT) andAmazon.com(AMZN), those fears have been laid to rest, leading him to think that these three retailers will keep their pandemic market-share gains.</p>\n<p>Second, he also likes the company’s expanding partnerships with key brands, includingLevi Strauss(LEVI), Ulta Beauty (ULTA), andWalt Disney(DIS). He notes that these high-profile agreements with popular consumer brands could be a “tipping point for vendors,” as they drive more and more traffic to Target.</p>\n<p>Finally, Drbul is upbeat about the U.S. consumer in 2021: While unemployment remains an issue, government stimulus and greater savings rates should allow for more shopping. “We expect Target to fully participate in the discretionary spending increase in 2021, led by its apparel offering.”</p>\n<p>Target stock is up 1.4% to $175 in recent trading. The shares are up 66% in the past 12 months but have fallen 2.2% year to date. Other analysts have also argued that therecent selloff is overdone.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Buy Target Stock on the Dip, Analyst Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBuy Target Stock on the Dip, Analyst Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-08 23:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/buy-target-stock-on-the-dip-analyst-says-51615214880?mod=hp_LATEST><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Targetstock soared in 2020, as the Covid-19 pandemic funneled millions of new customers to its stores and website, yet that rally has stalled as investors look toward an end to the crisis. Yet ...</p>\n\n<a href=\"https://www.barrons.com/articles/buy-target-stock-on-the-dip-analyst-says-51615214880?mod=hp_LATEST\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".DJI":"道琼斯",".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index"},"source_url":"https://www.barrons.com/articles/buy-target-stock-on-the-dip-analyst-says-51615214880?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1130305981","content_text":"Targetstock soared in 2020, as the Covid-19 pandemic funneled millions of new customers to its stores and website, yet that rally has stalled as investors look toward an end to the crisis. Yet Guggenheim argues that Target’s advantage is here to stay, and that selloff is a buying opportunity.\nAnalyst Robert Drbul boosted his rating on Target (ticker: TGT) to Buy from Neutral, and established a $200 price target on Monday. He writes that he has “admired the execution and performance of the company over the past year and have been waiting for a pullback to become more constructive.” With the shares off some 6% last week,despite another upbeat earnings report, that time has come.\nDrbul sees three main reasons to be bullish on Target. First, he notes the tremendous growth the company saw last year, when it grew revenue by $15 billion, more than the company had grown over the prior 11 years combined.\n“Target proved fulfill-from-store can work, driving share gains and meeting an unprecedented demand led by a rise in digital demand,” he writes, and while he had “stubbornly been skeptical” of the company’s ability to execute as well as major competitors such asWalmart(WMT) andAmazon.com(AMZN), those fears have been laid to rest, leading him to think that these three retailers will keep their pandemic market-share gains.\nSecond, he also likes the company’s expanding partnerships with key brands, includingLevi Strauss(LEVI), Ulta Beauty (ULTA), andWalt Disney(DIS). He notes that these high-profile agreements with popular consumer brands could be a “tipping point for vendors,” as they drive more and more traffic to Target.\nFinally, Drbul is upbeat about the U.S. consumer in 2021: While unemployment remains an issue, government stimulus and greater savings rates should allow for more shopping. “We expect Target to fully participate in the discretionary spending increase in 2021, led by its apparel offering.”\nTarget stock is up 1.4% to $175 in recent trading. The shares are up 66% in the past 12 months but have fallen 2.2% year to date. Other analysts have also argued that therecent selloff is overdone.","news_type":1},"isVote":1,"tweetType":1,"viewCount":106,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":329091540,"gmtCreate":1615185758180,"gmtModify":1704779246338,"author":{"id":"3572376808674205","authorId":"3572376808674205","name":"AyuNg","avatar":"https://static.tigerbbs.com/33c17b1cfc356a899e4c538a20ed5530","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572376808674205","authorIdStr":"3572376808674205"},"themes":[],"htmlText":"Gosh&nbsp;","listText":"Gosh&nbsp;","text":"Gosh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/329091540","repostId":"1171023317","repostType":4,"repost":{"id":"1171023317","kind":"news","pubTimestamp":1615180875,"share":"https://ttm.financial/m/news/1171023317?lang=&edition=fundamental","pubTime":"2021-03-08 13:21","market":"us","language":"en","title":"Elon Musk lost $27 billion last week","url":"https://stock-news.laohu8.com/highlight/detail?id=1171023317","media":"cnn","summary":"New York (CNN Business)Elon Musk's net worth plunged last week as tech stocks got hammered and Tesla","content":"<p>New York (CNN Business)Elon Musk's net worth plunged last week as tech stocks got hammered and Tesla shares' stunning rise quickly unraveled.</p>\n<p>Wall Street is growing increasingly nervous about rising bond yields, which could make borrowing more expensive. That could eat into corporate profits, which is why investors have begun to reverse some of the positions they took over the past year in high-growth but risky tech stocks like Tesla.</p>\n<p>Tesla's (TSLA) stock fell 11.5% last week. Musk, who owns nearly 18% of Tesla's shares, bore most of the brunt of that massive sell-off.</p>\n<p>Musk's wealth fell by $27 billion last week, according to Bloomberg's Billionaires Index. The decline in his net value is roughly equal to the entire fortune held by Dyson founder James Dyson -- the 52nd richest person in the world, according to Bloomberg.</p>\n<p>Musk and Amazon (AMZN) CEO Jeff Bezos have been swapping places atop Bloomberg's list of richest people in the world since January. But Musk now sits in a distant second place: $157 billion, compared to Bezos' net worth of $177 billion. Musk remains $21 billion ahead of Microsoft (MSFT) founder Bill Gates, who remains the third-richest person on the planet.</p>\n<p>Tesla's stock gained 743% in 2020, propelling it to No. 5 on the list of most valuable companies on the stock market. After losing 15% this year, Tesla's stock has since fallen to No. 7, behind Facebook (FB) and Berkshire Hathaway (BRKA) but ahead of JPMorgan Chase (JPM).</p>\n<p>Even if Tesla's stock continues to sink, Musk still stands to become much richer in 2021 and beyond.</p>\n<p>He received four grants to buy 8.4 million Tesla shares in 2020. Each of those was worth $5 billion at Friday's closing price, although some of that will be shaved off because Musk will have to pay the exercise price. Musk will probably receive three additional options grants this year, each as large and as lucrative as those he received in 2020.</p>\n<p>Musk has not exercised any of his options. Executives typically exercise them when they are due to expire, or to free up cash. Musk has never sold Tesla shares.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Elon Musk lost $27 billion last week</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nElon Musk lost $27 billion last week\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-08 13:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://edition.cnn.com/2021/03/07/tech/elon-musk-net-worth/index.html><strong>cnn</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>New York (CNN Business)Elon Musk's net worth plunged last week as tech stocks got hammered and Tesla shares' stunning rise quickly unraveled.\nWall Street is growing increasingly nervous about rising ...</p>\n\n<a href=\"https://edition.cnn.com/2021/03/07/tech/elon-musk-net-worth/index.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://edition.cnn.com/2021/03/07/tech/elon-musk-net-worth/index.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1171023317","content_text":"New York (CNN Business)Elon Musk's net worth plunged last week as tech stocks got hammered and Tesla shares' stunning rise quickly unraveled.\nWall Street is growing increasingly nervous about rising bond yields, which could make borrowing more expensive. That could eat into corporate profits, which is why investors have begun to reverse some of the positions they took over the past year in high-growth but risky tech stocks like Tesla.\nTesla's (TSLA) stock fell 11.5% last week. Musk, who owns nearly 18% of Tesla's shares, bore most of the brunt of that massive sell-off.\nMusk's wealth fell by $27 billion last week, according to Bloomberg's Billionaires Index. The decline in his net value is roughly equal to the entire fortune held by Dyson founder James Dyson -- the 52nd richest person in the world, according to Bloomberg.\nMusk and Amazon (AMZN) CEO Jeff Bezos have been swapping places atop Bloomberg's list of richest people in the world since January. But Musk now sits in a distant second place: $157 billion, compared to Bezos' net worth of $177 billion. Musk remains $21 billion ahead of Microsoft (MSFT) founder Bill Gates, who remains the third-richest person on the planet.\nTesla's stock gained 743% in 2020, propelling it to No. 5 on the list of most valuable companies on the stock market. After losing 15% this year, Tesla's stock has since fallen to No. 7, behind Facebook (FB) and Berkshire Hathaway (BRKA) but ahead of JPMorgan Chase (JPM).\nEven if Tesla's stock continues to sink, Musk still stands to become much richer in 2021 and beyond.\nHe received four grants to buy 8.4 million Tesla shares in 2020. Each of those was worth $5 billion at Friday's closing price, although some of that will be shaved off because Musk will have to pay the exercise price. Musk will probably receive three additional options grants this year, each as large and as lucrative as those he received in 2020.\nMusk has not exercised any of his options. Executives typically exercise them when they are due to expire, or to free up cash. Musk has never sold Tesla shares.","news_type":1},"isVote":1,"tweetType":1,"viewCount":5,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":329093451,"gmtCreate":1615185705673,"gmtModify":1704779245023,"author":{"id":"3572376808674205","authorId":"3572376808674205","name":"AyuNg","avatar":"https://static.tigerbbs.com/33c17b1cfc356a899e4c538a20ed5530","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572376808674205","authorIdStr":"3572376808674205"},"themes":[],"htmlText":"to him is just a small money&nbsp;","listText":"to him is just a small money&nbsp;","text":"to him is just a small money","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/329093451","repostId":"1171023317","repostType":4,"isVote":1,"tweetType":1,"viewCount":82,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}